Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE agreement could open up whole new area of cancer diagnostics

The deal is with the Barts Cancer Institute and focuses on the breakthrough made by its researchers in determining the role of megakaryocytes
patient with doctor
The technology may provide a weapon in the fight against prostate cancer

ANGLE PLC (LON:AGL, OTCQX:ANPCY) has signed an option agreement over an advance that may open a “whole new area of cancer diagnostics”.

The deal is with the Barts Cancer Institute and focuses on the breakthrough made by its researchers in determining the role of megakaryocytes.

Found in the blood they correlate closely with survival rates for patients with prostate cancer.

Their presence and abundance could allow doctors to more precisely tailor treatments so they are more effective.

Partsortix holds key to harvesting 

ANGLE’s Parsortix liquid biopsy is the only device currently able to harvest megakaryocytes.

Queen Mary University of London, of which the Barts Cancer Institute is a part, has filed two worldwide patent applications related to its work.

The AIM-listed med-tech firm has agreed to cover the costs of that process in return for a two-year option over patents covering any medical therapeutic, diagnostic, or prophylactic application. 

WATCH: ANGLE inks agreement with world-leading molecular testing provider

READ: Broker targeting near-tripling in ANGLE's share price as Parsortix development strides forward

The company’s chief executive, Andrew Newland, said: "This deal further strengthens ANGLE's intellectual property position in the fast-emerging liquid biopsy market.

“Use of the Parsortix system is driving new discoveries by key opinion leaders and customers and ANGLE is the obvious partner to drive their commercialisation so we expect to see other similar developments over time continually strengthening the Company's position in the market."

ANGLE shares were 2.5% higher in morning trade at 34.5p, but small-cap broker finnCap believes the stock has much further to go.

“We make no changes to our forecasts and retain our 100p price target, which is based on a DCF [discounted cash flow] analysis,” said analyst Mark Brewer in a short note to clients.

“But [we] point to the significant long-term value potential additional value that could be generated by any clinical applications arising from the combination of Parsortix and the downstream analysis of captured megakaryocytes.”

---adds broker comment and share price---

View full AGL profile View Profile

ANGLE plc Timeline

Newswire
October 12 2017

Related Articles

Patient undergoing radiotherapy
August 02 2017
Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use